10-Q: Citius Pharmaceuticals Reports Q1 2025 Results, Cautions on Going Concern

Citius Pharmaceuticals reports a net loss for Q1 2025 and expresses concerns about its ability to continue as a going concern without additional funding.

Summary

• Citius Pharmaceuticals reported a net loss of $10.3 million for the three months ended December 31, 2024, compared to a net loss of $9.2 million for the same period in 2023.
• The company's research and development expenses decreased to $2.1 million from $2.6 million year-over-year, primarily due to the completion of the Phase 3 trial for Mino-Lok.
• General and administrative expenses increased to $5.4 million from $3.7 million year-over-year, driven by pre-launch sales and market activities for LYMPHIR.
• The company's cash and cash equivalents stood at $1.1 million as of December 31, 2024.
• Citius Pharma estimates that its available cash resources will be sufficient to fund its operations through March 2025, raising substantial doubt about its ability to continue as a going concern.
• The company is actively pursuing capital raise initiatives, including through its subsidiary Citius Oncology, to extend its cash runway.
• Citius Oncology received FDA approval for LYMPHIR in August 2024 and is preparing for commercial launch.
• The company executed a 1-for-25 reverse stock split effective November 25, 2024, to regain compliance with Nasdaq's minimum bid price requirement.
• Citius regained compliance with the Nasdaq's $1.00 per share requirement on December 18, 2024.
• The company completed sales of common shares through an 'at the market' offering in January 2025, generating gross proceeds of $0.5 million.
• On January 7, 2025, the company entered into a securities purchase agreement for a registered direct offering, expecting net proceeds of approximately $2.7 million.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative due to the increased net loss, going concern uncertainty, and need for additional capital, balanced by the FDA approval of LYMPHIR and efforts to secure funding.

Positives

• FDA approval for LYMPHIR was received in August 2024, paving the way for commercial launch.
• Citius regained compliance with Nasdaq's minimum bid price requirement following a reverse stock split.
• The company is actively pursuing capital raise initiatives to address its financial concerns.
• Research and development expenses decreased due to the completion of the Phase 3 trial for Mino-Lok.

Negatives

• The company reported a net loss of $10.3 million for Q1 2025, an increase from the previous year.
• Citius Pharma estimates its cash will only fund operations through March 2025, raising going concern doubts.
• The company has a negative working capital of approximately $26.5 million at December 31, 2024.

Risks

• The company's ability to continue as a going concern is dependent on securing additional funding.
• There is no assurance that the company will be successful in raising the needed capital or that the proceeds will be received in a timely manner.
• The company has incurred operating losses since inception and has not yet realized any revenues from its operations.
• The company is subject to risks common to companies in the pharmaceutical industry, including regulatory approval, market acceptance, and competition.

Future Outlook

The company expects that research and development expenses will continue to decrease in fiscal 2025 as it continues to focus on the commercialization of LYMPHIR and because it has completed the Phase 3 trial for Mino-Lok. The company will need to raise additional capital in the future to support its operations beyond March 2025.

Management Comments

• Management believes that inflation has not had a material effect on our results of operations.

Industry Context

Citius Pharmaceuticals operates in the competitive biopharmaceutical industry, facing challenges common to companies in this sector, including the need for regulatory approvals, market acceptance of products, and competition from larger companies.

Comparison to Industry Standards

• It is difficult to compare Citius Pharmaceuticals directly to industry standards without specific benchmarks for companies of similar size and stage of development.
• However, the company's reliance on raising capital through equity and debt financing is a common practice among development-stage biopharmaceutical companies.
• The company's focus on critical care products and oncology aligns with areas of high unmet medical need and potential market opportunity.
• The company's licensing agreements with companies like Eisai and Dr. Reddys are typical strategies for acquiring and developing promising drug candidates.

Stakeholder Impact

• Shareholders face the risk of dilution if the company raises additional capital through equity offerings.
• Employees' job security is uncertain due to the company's financial situation.
• Customers (patients) may benefit from the commercialization of LYMPHIR.
• Suppliers and creditors face the risk of non-payment if the company's financial situation does not improve.

Next Steps

• The company plans to focus on the commercialization of LYMPHIR.
• The company needs to secure additional funding to support its operations beyond March 2025.
• The company will continue to develop its product candidates, including seeking regulatory approval and protecting its intellectual property.

Key Dates